Am. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (, European Heart Journal. Otsuka, F. et al. Mauri, L. et al. A.V.F. from 8 AM - 9 PM ET. is a consultant for Abbott Vascular, Boston Scientific, Celonova, Cook Medical, Cordis, CSI, Edwards Lifescience, Lutonix Bard, Medtronic, OrbusNeich Medical, ReCore, Sinomededical Technology, Spectranetics, Surmodics, Terumo Corporation, W. L. Gore and Xeltis. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. Nature Reviews Cardiology thanks A. Kastrati, P. Serruys and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Cardiol. S.T., H.J., A.S., A.C., H.M., D.C., M.E.R., F.D.K., A.G., R.V. 10, 23752387 (2017). Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Comparison of in vivo longitudinal strength and conformability following stent implantation in rabbit iliac artery. In 1432 patients (1857 lesions/ 2148 stents) with acute coronary syndromes, angioplasty was performed with Cordis 6F diagnostic catheters. J. Biomed. "Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market," said Seth Fischer, Company Group Chair and Worldwide Chairman, Cordis Corporation. You've successfully added to your alerts. Arterioscler. Kufner, S. et al. Byrne, R. A., Stone, G. W., Ormiston, J. Presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2018). Eighty percent (80%) of the sirolimus is released during the first 30 days. Heart J. Circulation 103, 28162821 (2001). official website and that any information you provide is encrypted N. Engl. , . "Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. It is also the longest-studied drug-eluting stent, with over 200 medical trials having been carried out and 155,000 patients observed. She has been with theheart.org since 2000, and specializes in interventional cardiology. 33, 5561 (2016). Guagliumi, G. et al. 5, 321329 (2016). To safely perform angioplasties in acute coronary syndromes with very low contrast volume using Cordis diagnostic catheters and thereby improve the cardiovascular and renal outcomes. Galloe, A. M. et al. Endothelial barrier protein expression in biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting metallic stents. EuroIntervention 12, e1366e1374 (2016). She studied literature at McGill University and the University of Cape Town and received her graduate degree in journalism from the University of British Columbia, specializing in health reporting. Surg. 70, 607619 (2017). BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. Company to Focus on Areas of Significant Patient Need in Cardiovascular Disease. But as Simon observed, the timing of the Cypher's demise is "ironic," coming as it does on the heels of trial results like EXCELLENT and SORT-OUT 4, which have suggested equivalency between the Cypher and Xience stents. Stent design, stent material, strut thickness and vessel-wall coverage all influence clinical outcomes, and thin-strut DES are the standard. Am. New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets. Cardiovasc. J. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. 10, 462473 (2017). The CYPHER Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length < 30 mm in native coronary arteries with a reference vessel diameter of > 2.5 to < 3.5 mm. Impact of stent strut design in metallic stents and biodegradable scaffolds. JACC Cardiovasc. Coronary Artery Stents - StatPearls - NCBI Bookshelf J.Med. Sign up to get PRNs top stories and curated news delivered to your inbox weekly! Correspondence to Cardiovasc. Eur. Coronary angioplasty (AN-jee-o-plas-tee), also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Jensen, L. O. et al. Tada, N. et al. Your use of the information on this site is subject to the terms of our Legal Notice. Never before have cardiologists been faced with so many choices of stent, each with its own unique design. In a separate news release today, Cordis' parent company, Johnson & Johnson, announced the financial implications of Cordis' restructuring plans. Introduction. A regular follow-up of the patients was performed 30 days after the procedure. J. When typing in this field, a list of search results will appear and be automatically updated as you type. Google Scholar. Please use this form to submit your questions or comments on how to make this article more useful to clinicians. And while he admits the newer stents have the advantage of being much more deliverable, he maintains there are still circumstances in which having the Cypher on hand would be a welcome option. 39, 213260 (2017). Closed versus open cell stent for high-risk percutaneous coronary interventions in ST-elevation acute myocardial infarction: the Closed versus Open Cells stent for High risk percutaneous coronary Interventions in ST-Elevation acute myocardial infarction (COCHISE) pilot study. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Together, these businesses share the common goal of providing lasting and minimally invasive treatments to improve and extend the lives of patients suffering from cardiovascular disease. These businesses generated 2010 sales of $1.9 billion*, representing an operational growth rate of 8 percent versus the prior year. CYPHER coronary stents and risk of thrombosis - National Center for BMJ 350, h1618 (2015). Before 36, 21472159 (2015). Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. Switch-over of angioplasty to the radial route was performed in five cases due to associated aortic/iliac obstructive lesions. 79, 26412647 (2015). For more information about Cordis please visit: www.cordis.com (this site is intended for US visitors only). Rev. 16, 13681372 (2010). Am. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. 03 August 2022, Cardiology and Therapy J. Invasive Cardiol. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. In the meantime, to ensure continued support, we are displaying the site without styles First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Clin. Circulation 131, 322324 (2015). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). reviewed and edited the manuscript before submission. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. Bioengineering 5, E71 (2018). The . Acute coronary syndrome (ACS) comprises a spectrum of hemodynamically significant coronary artery disease that most commonly arises from plaque rupture and/or erosion, leaving the lipid-rich plaque core exposed to the circulation. This is an impressive outcome and a testament to the efficacy of the CYPHER(R) stent. R.V. J. Vasc. The CYPHER stent, a metal device that is coated with sirolimus, was approved in April 2003 by the US Food and Drug Administration (FDA) for use in angioplasty procedures. Am. Dynamics in the DES market have changed considerably in recent years and continue to evolve in areas such as demand, pricing and reimbursement, and regulatory requirements for breakthrough new technologies. Rogers, C. & Edelman, E. R. Endovascular stent design dictates experimental restenosis and thrombosis. 29, 10411049 (2018). 06 December 2021, Access Nature and 54 other Nature Portfolio journals, Get Nature+, our best-value online-access subscription, Receive 12 print issues and online access, Prices may be subject to local taxes which are calculated during checkout. J. A regular follow-up of the patients was performed 30 days after the procedure. Imaging 8, 451460 (2015). and R.V. Coll. 26 deaths in total were observed in this series; 16 of these patients had cardiogenic shock (7 late presenters), and three patients expired after discharge due to possible acute stent thrombosis. Meredith, I. T. et al. Morlacchi, S. & Migliavacca, F. Modeling stented coronary arteries: where we are, where to go. Overall, the company expects to reduce 900 - 1,000 positions, subject to any consultation procedures on these plans in countries where required. Kuramitsu, S. et al. Please see our. Shelley Wood is a journalist for theheart.org, part of the WebMD Professional Network. Vasc. 19, 818819 (2018). Together, these businesses share the common goal of providing lasting and minimally invasive treatments to improve and extend the lives of patients suffering from cardiovascular disease. PubMed Adriaenssens, T. et al. The Cypher's one-time dominance has been eclipsed by the Xience/Promus everolimus-eluting devices, as well as the rise of other platforms, using other drugs. Circulation 136, 10071021 (2017). Contact Us with any questions or search this site for more information. Bridgewater, NJ (June 15, 2011) -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. 21 June 2022, Nature Communications You are now leaving jnj.com. Torii, S. et al. Circulation 91, 29953001 (1995). "In hindsight, looking back, you have to wonder if today's announcement wasn't planned internally by Cordis several months back," Kandzari observed. J. Invasive Cardiol. Am. Inclusion in an NLM database does not imply endorsement of, or agreement with, Scientific Reports Heart J. Qual. Vranckx, P. et al. The patient, who was treated in 1999 with the CYPHER(R) stent at the age of 75 after her coronary angiography showed a significant, single, de novo lesion in the proximal left anterior descending (LAD) artery, under-went further invasive follow-up revealing a sustained anti-proliferative effect of the CYPHER(R) stent by both angiography and IVUS examination in 2009. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. Copyright 2023. Cordis Announces Return to the Drug-Eluting Stent Market - Pharmacy Times But Cordis has always been on the forefront of innovation, [and it's clear] they are going into the next frontier.". The .gov means its official. These businesses will also evaluate opportunities in areas where significant need and promising technologies exist. Pathophysiology of restenosis Stent-induced restenosis involves a complex interplay of biological events. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): arandomised single-blind trial. / PRNewswire / -- Cardinal Health today announced that it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health's interventional vascular business, to sell Biosensors' coronary stent portfolio. All contrast injections were given by hand. This website also contains material copyrighted by 3rd parties. Circulation 123, 14001409 (2011). The follow-up procedure was broadcast live during the 2009 meeting of the Latin America Society of Interventional Cardiology (SOLACI, Rio de Janeiro - Brazil). Cardiol. JACC Cardiovasc. 39, 24482456 (2018). Varenne, O. et al. Unlicensed competition from products that infringe Cordis patents, both owned and licensed, has eroded CYPHER Stent pricing, sales and market share, and has dampened the prospects for NEVO Stent commercialization. You must declare any conflicts of interest related to your comments and responses. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Cordis Corporation and/or Johnson & Johnson. 10, 248260 (2013). J. J. These statements are based on current expectations of future events. Cordis Announces Discontinuation Of Nevo Sirolimus-Eluting Coronary Stent 69, 616624 (2017). Very late pathological responses to cobalt-chromium everolimus-eluting, stainless steel sirolimus-eluting, and cobalt-chromium bare metal stents in humans. Copy and send link X. Cordis, a Johnson & Johnson company, has launched a bare metal stent system Presillion Plus in Europe. The site is secure. Am. As a library, NLM provides access to scientific literature. Subsequently, newer-generation DES were introduced with thinner struts, different scaffold designs (to improve deliverability while maintaining radial strength), different durable and biodegradable polymers and in some cases no polymer (to improve vascular biocompatibility) and new antiproliferative drug types and doses. The company will continue to focus on cardiovascular care through its Biosense Webster and Cordis businesses: Biosense Webster will continue to build and expand on its global leadership position in the $2.5 billion electrophysiology (EP) market, as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. & Himes, R. H. Understanding tubulin-taxol interactions: mutations that impart taxol binding to yeast tubulin. J. Med. Stay up-to-date with breaking news, conference slides, and topical videos covering the spectrum of CVD. Nakazawa, G. et al. The experience with the Cypher Sirolimus-Eluting Coronary Stent (Cordis Corp., Miami Lakes, FL) at Arkansas Heart Hospital progressed from anxious anticipation to complete removal of the stent from inventory in a 6-month period. Lee, S. Y. et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Mater. Under a long-term distribution agreement, "According to veterinary doctors, ectopia, Dictionary, Encyclopedia and Thesaurus - The Free Dictionary, the webmaster's page for free fun content, CORDIS RESULTS OF 10-YR CYPHER STENT FOLLOW-UP, LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $100,000 in Cardinal Health, Inc. to Contact the Firm, Langham exploring opportunities in the region after its 2019 Dubai launch, Cordis & Medinol partnership wins US FDA's approval for EluNIR drug-eluting stent (DES) for treating blockages to their coronary arteries, Complete Ectopia Cordis: A Case Report and Literature Review, Cordillera Women Education and Research Center, CORDIS - Community Research & Development Information Service. Cardiol. Cardiovasc. Sciahbasi, A. et al. Catheter. This leads to a cascade of events, including activation of platelets and the . Heart J. Bangalore, S., Toklu, B., Patel, N., Feit, F. & Stone, G. W. Newer generation ultra-thin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: a meta-analysis of randomized trials. Lancet 391, 4150 (2018). J. Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions". The company will also stop the manufacture of CYPHER and CYPHER SELECT Plus Sirolimus-Eluting Coronary Stents by the end of 2011. Cardiovasc. The other authors declare no competing interests. Provided by the Springer Nature SharedIt content-sharing initiative, Cardiovascular Intervention and Therapeutics (2023), Journal of Thrombosis and Thrombolysis (2022), Nature Reviews Cardiology (Nat Rev Cardiol) Puranik, A. S., Dawson, E. R. & Peppas, N. A. However, the first-generation DES had substantial drawbacks, including delayed healing, local hypersensitivity reactions and neoatherosclerosis, which all led to a steady increase in major adverse cardiovascular events over time. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. Primary angioplasty was performed in 457 cases. Catheter. A randomized comparison of coronary-stent lacement and balloon angioplasty in the treatment of coronary artery disease. Mridha, N. et al. Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual anti-platelet therapy. 12, 1 (2015). Buddy wires were used in 36 cases. Interv. Heart J. Cardiovasc. Because restenosis within the stented region of a heart artery is caused by tissue growth, some stents (called drug-eluting stents) have medication on them to inhibit or prevent this tissue growth. Cordis/Johnson & Johnson made the announcement in a press release earlier this morning, reportedly surprising some of the investigators for the US-based NEVO III trial, led by Dr David Kandzari (Piedmont Heart Institute, Atlanta, GA) and Dr Daniel Simon (University Hospitals Case Medical Center, Cleveland, OH). Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mild reversible nephropathy (CIN) was observed in six patients. Lancet 380, 14821490 (2012). Vascular response to bioresorbable polymer sirolimus-eluting stent versus permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. Cordis Announces Discontinuation Of Nevo Sirolimus-Eluting Coronary Stent, Company To Focus On Areas Of Significant Patient Need In Cardiovascular Disease. Product catalog - Cordis - PDF Catalogs | Technical Documentation J. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Welcome to Cordis Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The business will focus on access, diagnostic and therapeutic products for cardiology procedures, products to diagnose, access and treat lower extremity disease, and the INCRAFT Stent-Graft System, the company's new investigational device for treating abdominal aortic aneurysm (AAA). Wilson, G. J. et al. https://medical-dictionary.thefreedictionary.com/cordis, On March 2, after months of rumor and speculation, Johnson & Johnson finally sold its, Campbell Rogers, M.D., Chief Scientific Officer and Global Head R&D at, The Company explained that the "biggest variable driving these results" was the "disappointing performance" of the. All Rights Reserved. Tirofiban was used in 99% cases with adjusted dosages based on the creatinine values. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Ormiston, J. Google Scholar. By signing up you agree to receive content from us. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. 10, 688700 (2014). https://doi.org/10.1038/s41569-019-0234-x, DOI: https://doi.org/10.1038/s41569-019-0234-x. Sirolimus-eluting coronary stents: a review - PMC - National Center for All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. 29, 483490 (2016). Cardiol. Enter the email you used to register to reset your password. 65, 24962507 (2015). Wilson, G. J. et al. STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus versus biolimus A9-eluting stent implantation): a randomised controlled trial. Cordis CorporationCordis Corporation, a Johnson & Johnson company, specializes in the development and manufacture of interventional vascular technology. and A.V.F. Interv. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. Vasc. Heart Assoc. Drug-Eluting Stents | Circulation - AHA/ASA Journals Lancet 392, 940949 (2018). Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Polymer-free Biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Lancet 379, 13931402 (2012). Cardiol. Coll. Res. Accuracy of OCT, grayscale IVUS, and their combination for the diagnosis of coronary TCFA: an ex vivo validation study. This content is available for meeting attendees and/or Platinum Members, Company to Focus on Areas of Significant Patient Need in Cardiovascular Disease BRIDGEWATER, N.J.,Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO Sirolimus. R.V. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Cordis will expand its portfolio of vascular solutions for endovascular and cardiology procedures, a $12 billion market. A key trial showing the efficacy of CYPHER(R) stent found that up to 5 years after receiving the stent, the risk of restenosis of the artery is reduced by 60 - 70% compared to an uncoated stent. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. Fujii, K. et al. BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will. Navarese, E. P. et al. 373, 20382047 (2015). EuroIntervention 11, e1619e1626 (2016). the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Eur. Internet Explorer). Nature Reviews Cardiology Torrado, J. et al. Heart Assoc. Although first-generation DES Cypher (sirolimus-eluting stent; Cordis Corporation, Johnson & Johnson, Warren, NJ) and Taxus (paclitaxel-eluting stent; Boston Scientific Corporation, Natick, Mass) have effectively achieved their main goal, reducing restenosis across virtually all lesion and patient subsets, their safety has been limited by subopt. Acute Cardiovascular Care, https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model. Nakazawa, G. et al. Recent advances in drug eluting stents. Cordis Announces Return to the Drug-Eluting Stent Market - PR Newswire To comment please, Comments on Medscape are moderated and should be professional in tone and on topic. CAS Do Not Sell or Share My Personal InformationLimit the Use of My Sensitive Personal InformationCookie Settings. Open Access 3,39-41 These ex vivo studies demonstrated a lack of . Polymer-free drug-coated coronary stents in patients at high bleeding risk. Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. Receive the the latest news, research, and presentations from major meetings right to your inbox. Habib, A. 7, e011245 (2018). 6, 370377 (2013). Drug-eluting coronary stents: insights from preclinical and pathology studies. J. In 76% of cases, iodixanol was used. She can be reached at SMWood@webmd.net. Comparison of vascular responses following new-generation biodegradable and durable polymer-based drug-eluting stent implantation in an atherosclerotic rabbit iliac artery model. Gore and Xeltis. Cardiovasc. JACC Cardiovasc. 30, 103109 (2019). Richard Grimes, Andrew Beall, and Jeremy Harman formed the contemporary ensemble, CORDIS, in Boston, MA in 2008. Cordis | definition of cordis by Medical dictionary the contents by NLM or the National Institutes of Health. 70 patients had cardiogenic shock at presentation. These trials, from the initial RAVEL trial in 2001 to this latest ten-year follow-up, have proven the CYPHER(R) stent's safety and effectiveness. Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Am. J. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. Cordis to Stop Making Cypher, Nevo Stents | MedPage Today Sakamoto, A., Jinnouchi, H., Torii, S., Virmani, R. & Finn, A. V. Understanding the impact of stent and scaffold material and strut design on coronary artery thrombosis from the basic and clinical points of view. Taniwaki, M. et al. 38, 10341043 (2017). Foin, N. et al. The company intends to close two manufacturing facilities: Cashel, Ireland, where the NEVO Stent was to be produced, and San German, Puerto Rico, the manufacturing site for the CYPHER Stent products. 177, 800808 (2014). Huynh, K. Antiplatelet therapy: risks and benefits of extended DAPT after stenting. Cardiovasc. J. A variety of coronary stents from various companies were used. In a history of impressive CYPHER(R) stent data announcements at ESC in Stockholm, Marie Claude Morice, M.D., Institut Cardiovasculaire Paris Sud, had presented the initial results of the highly successful RAVEL trial, the first CYPHER(R) stent randomized trial, at the Annual Congress of the European Society of Cardiology in 2001.